Cadrenal Therapeutics, Inc. · NASDAQ:CVKD
Cadrenal Therapeutics — Investor Presentation (May 2024)
29 slides from Cadrenal Therapeutics's investor presentation, May 2024
Slide 1: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. NASDAQ: CVKD May 2024
Slide 2: Caution Concerning Forward-looking Statements
Caution Concerning Forward-looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward- looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about fut
Slide 3: Cadrenal Therapeutics Overview
Cadrenal Therapeutics Overview: Late-stage Drug Company with Multiple Orphan-drug and Fast-track Designations Developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascul
Slide 4: Key Investment Highlights for Tecarfarin Opportunity
Key Investment Highlights for Tecarfarin Opportunity NO approved anticoagulation therapies for rare cardiovascular High Level of 1 Unmet Need conditions requiring chronic anticoagulation, including LVADs, ESKD with AFib, and APS Tecarfarin is a next-generation VKA that leverages the well- Proven Mec
Slide 5: Leadership Team: Clinical to Commercial Expertise
Leadership Team: Clinical to Commercial Expertise Quang Pham Douglas Losordo, MD Matthew Szot, CPA Jeff Cole CEO & Founder, Chairman Chief Medical Officer Chief Financial Officer Chief Operating Officer John R. Murphy Steven Zelenkofske, DO Glynn Wilson, PhD Robert Lisicki Board Member Board Member
Slide 6: Scientific Advisory Board with Deep Experience in CV and Beyond
Scientific Advisory Board with Deep Experience in CV and Beyond Christopher Granger, MD Sean Pokorney, MD, MBA Eloine M. Hylek, MD, MPH Professor of Medicine in the Division of Cardiology, Electrophysiologist and Assistant Professor of Medicine, Duke University Professor of Medicine, Boston Universi
Slide 7: The Problem: Certain Rare Heart Conditions Lack Effective Anticoagulation
The Problem: Certain Rare Heart Conditions Lack Effective Anticoagulation Physicians are frustrated with warfarin outcomes and hesitant to prescribe DOACs more broadly, given the negative evidence in clinical trials SIGNIFICANT ISSUES WITH CURRENT THERAPIES FOR THESE PATIENTS Warfarin DOACs (Pradaxa
Slide 8: The Solution: Tecarfarin Aims to Solve Warfarin's Major Problems
The Solution: Tecarfarin Aims to Solve Warfarin’s Major Problems and Fill Significant Market Void SOLUTION: Tecarfarin SPECIFICALLY DESIGNED TO solve the warfarin metabolism problem, thereby x Warfarin: Unreliable metabolism MAJOR PROBLEM DECREASING RISK OF STROKE & BLEEDING for patients with certai
Slide 9: Attractive Addressable Market Opportunities
Attractive Addressable Market Opportunities U.S. market potential estimated more than $2 billion for three targeted rare indications Left Ventricular Assist Devices End-stage Approximately Kidney Disease with AFib >$2 Billion Combined Peak Annual Market Potential* (if approved by the FDA) Thrombotic
Slide 10: Financial Summary
Financial Summary Cap Table Q1 2024 Financial Results Cash (at 3/31/24) $6.6 million Operating Expenses (excluding non-cash items) $1.6 million Debt NONE Cash used in operating activities $1.8 million Common Shares Outstanding 16,008,469 Market Capitalization Warrants – Investors (avg. $1.75) 4,285,
Slide 11: Tecarfarin Clinical Development Pipeline
Tecarfarin Clinical Development Pipeline Potential 2024 catalysts for future milestones to build enterprise value Development Phase Discovery Preclinical Phase I Phase II Phase III Program Prioritized Target Indications Regulatory Strategy/Status Left Ventricular Assist Devices FDA Orphan Drug Desig
Slide 12: Why Cadrenal Now?
Why Cadrenal Now? Tecarfarin is targeted for indications where it is NOW CLEAR FROM DATA that warfarin FAILS to achieve sufficiently stable anticoagulation and DOACs have clinically NOT shown benefit Unmet Need Proven Improved Regulatory Large Commercial Certain rare cardiovascular Mechanism of Acti
Slide 13: Contact Us
Contact Us Quang Pham CEO & Founder quang.pham@cadrenal.com Matthew Szot CFO matthew.szot@cadrenal.com 13
Slide 14: Appendix
APPENDIX CADRENAL
Slide 15: Tecarfarin's Metabolic Advantage
Tecarfarin’s Metabolic Advantage Tecarfarin is metabolized via an alternate pathway that is abundant and essentially insaturable, thereby avoiding the bottleneck in the CYP450 pathway where warfarin in metabolized. Warfarin Tecarfarin CYP450 Human CarboxylEsterase 2 (CES2) Drug interactions Genetic
Slide 16: Warfarin Metabolism via CYP450 is Complicated by Competitors, Inhibitors and Inducers
Warfarin Metabolism via CYP450 is Complicated by Known Competitors, Inhibitors and Inducers and the Established Impact of Genetic Variants Enzymes Substrates Inhibitors Inducers amlodipine, simvastatin, ciprofloxacin, simvastatin, efavirenz, warfarin, amiodarone, ketoconazole, ritonavir, pentobarbit
Slide 17: Tecarfarin is Metabolized via the Human Carboxyl Esterase Pathway (CES2)
Tecarfarin is Metabolized via the Human Carboxyl Esterase 2 Pathway (CES2) Provides More Effective, Safe, and More Consistent Anti-coagulation Enzymes Substrates Inhibitors Inducers CES2 Substrate Drugs amlodipine, simvastatin, ciprofloxacin, simvastatin, efavirenz, Antiplateletes/Anticoagulants CNS
Slide 18: Vitamin K Antagonism Inhibits Multiple Factors in the Clotting Cascade
Vitamin K Antagonism Inhibits Multiple Factors (II, VII, IX, X, Proteins C & S) in the Clotting Cascade vs. Single Targets of Newer Agents Proven mechanism of action resulting in clinically meaningful anticoagulation in certain conditions where DOACs have failed SINGLE-TARGET CONTACT ACTIVATION DOAC
Slide 19: Tecarfarin Demonstrates TTR Above Anticoagulation Control Threshold
Tecarfarin Demonstrates TTR Above Anticoagulation Control Threshold Phase 2/3 trial shows Tecarfarin provides stable anticoagulation with >72% TTR overall and across key subgroups Phase 2/3 Trial completed (N=607) Key Tecarfarin Findings o Tecarfarin vs. well-controlled warfarin trial Tecarfarin o R
Slide 20: Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves
ESKD + AFib LVAD APS Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves EXCESS RISK AND NO BENEFIT First Freedom Thromboembolic from EventEvent First Thromboembolic 1.0 Warfarin Probability of Event Free Survival 0.9 0.8 Trial terminated prematurely 0.7 due to an excess of thromboem
Slide 21: TTR Decreases with CKD Severity for AFib Patients on Warfarin
ESKD + AFib LVAD APS TTR Decreases with CKD Severity for AFib Patients on Warfarin AFib Patients with ESKD on Warfarin are Poorly Controlled with TTR of 42-51%, compared to the TTR goal of 70% or greater TTR of AFib patients with CKD on Warfarin by eGFR Group Time in Therapeutic Range (TTR)1,2,5 E
Slide 22: Phase 2/3 Trial Shows Tecarfarin is Well-Tolerated, with Fewer Hemorrhagic Events
ESKD + AFib LVAD APS Phase 2/3 Trial Shows Tecarfarin is Well-Tolerated for Stroke and Thrombus Prevention, with Fewer Hemorrhagic Events Tecafarin Warfarin Tecarfarin had fewer thrombotic events compared to warfarin 2 2 Randomized, double- blind clinical trial 1 N=607 0 0 0 Patients with indication
Slide 23: Significant Underserved Patient Populations
ESKD + AFib LVAD APS Significant Underserved Patient Populations Despite the significantly increased risk of stroke in ESKD patients with AFib, most patients are not anticoagulated due to the lack of evidence of benefit Use of warfarin in ESKD + AFib Patients1 (N=9,974)1 (N=47,480)2 100% 80% Most pa
Slide 24: Tecarfarin Phase 1 PK Trial in Stage 4 CKD Patients
ESKD + AFib LVAD APS Tecarfarin Phase 1 PK Trial in Stage 4 CKD Patients Provides Evidence that CKD Does Not Alter Tecarfarin Exposure While Warfarin Exposure is Increased Summary Table Result Highlights % change between Stage 4 CKD patients vs healthy subjects matched for each drug using a randomiz
Slide 25: Kidney Failure Has a Significant Impact on Warfarin PK vs Tecarfarin
ESKD + AFib LVAD APS Kidney Failure Has a Significant Impact on Warfarin PK vs Tecarfarin Tecarfarin metabolism not as impacted by kidney failure Percent Increase in Exposure for Chronic Kidney Disease Subjects vs Healthy subjects for Warfarin and Tecarfarin (n =23) 50 AUC 25 t1/2 45 20 40 44 20 Per
Slide 26: APS Patients Randomized to DOACs Have Increased Arterial Thrombosis Risk
ESKD + AFib LVAD APS APS Patients Randomized to DOACs Have Increased Arterial Thrombosis Risk TRIAL SITES RAPS UK (N = 116) Vitamin K Antagonists (VKAs) Patients with TRAPS Italy (N = 120) Ordi-Ros, et al. Spain (N = 190) Thrombotic APS R ASTRO-APS US (N = 48) N = 474 Direct Oral Anticoagulants (DOA
Slide 27: Guidelines on Anticoagulant Treatment in Antiphospholipid Syndrome
ESKD + AFib LVAD APS Summary of Guidelines Recommendations on Anticoagulant Treatment Prescription in Patients with Antiphospholipid Syndrome PATIENTS WITH DEFINITE APS Arterial thrombotic event (ischemic stroke, myocardial infarction, ESC, ASH, EULAR*,BSH, ISTH systemic embolism) with any positivit
Slide 28: Eliquis 2023 Commercial
Eliquis 2023 Commercial Eliquis highlights in its own commercial that you should not take for certain conditions. “Don’t take ELIQUIS if you have an artificial heart valve…” ELIQUIS is not for patients who have antiphospholipid syndrome (APS). 28
Slide 29: Premium Pay for High Value Cardiovascular Orphan Drugs
Premium Pay for High Value Cardiovascular Orphan Drugs Track record of recent transactions for orphan drugs in cardiovascular space Developed by MyoKardia and the company was Developed by FoldRx with $88 million in private subsequently acquired by BMS for $13 billion financing, before FoldRx was sub
Cadrenal Therapeutics — Investor Presentation (May 2024) on 6ix